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coli O157 hemolytic uremic syndrome due to municipal water
contamination.
Background. Knowledge of the long-term renal prognosis
of diarrhea associated hemolytic uremic syndrome (HUS) is
important for patient counseling and follow-up. However, esti-
mates of long-term risk are highly variable, with previous studies
not using a healthy control group.
Methods. A municipal water system in the small rural town
of Walkerton, Ontario, became contaminated with Escherichia
coli O157:H7 in 2000. A cohort of 19 children who recovered
from HUS was randomly age- and sex-matched to 38 children
with no symptoms at the time of the outbreak. Both groups
had detailed renal function testing 3 years after the outbreak,
including a random urine albumin to creatinine, glomerular fil-
tration rate estimated by Schwartz formula, and automated and
manual blood pressure measurements.
Results. There were no baseline differences between the
groups with respect to age (mean 4.8 years, range 1 to 15), sex,
or birth weight (mean 3.4 kg). In follow-up there were no dif-
ferences between the groups in body surface area (mean 1.0
m2), or in the methods by which renal function was assessed.
Compared to the group with no symptoms, patients with HUS
demonstrated more microalbuminuria [32% vs. 5%, relative
risk 4.8 (95% CI 1.1 to 22.0)], a nonsignificant trend toward
lower GFR (124 vs. 134 mL/min per 1.73m2), and no difference
in blood pressure.
Conclusion. Children may demonstrate microalbuminuria 3
years after recovering from HUS. Longer follow-up is needed
to determine if this finding has clinical relevance and utility.
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The hemolytic uremic syndrome (HUS), particularly
in children, is a main cause of acute renal failure world-
wide. Ninety percent of childhood cases of HUS are as-
sociated with diarrhea and gastroenteritis (D+ HUS),
and are due to Shiga-toxin producing Escherichia coli
[1]. With improved recognition and supportive care, more
patients are surviving the acute phase of D+ HUS. Un-
derstanding the long-term renal prognosis of D+ HUS
is critical for patient counseling, follow-up, and monitor-
ing. It informs the feasibility of future clinical trials, and
guides the necessity of screening after large population
outbreaks of Shiga toxin producing E. coli gastroenteri-
tis. However, the long-term risk of reduced glomerular
filtration rate (GFR), hypertension, and proteinuria af-
ter D+ HUS remains controversial. Our discussions with
pediatric nephrologists within Canada suggest different
estimates of these risks are communicated to patients, and
varying practice patterns exist with respect to follow-up
of those who recover from HUS.
We recently reviewed 49 HUS renal prognosis stud-
ies from 18 countries from the years 1950 to 2001 (pri-
mary studies referenced in [2]). When these studies were
considered together, 3476 children were followed for an
average of 4.4 years (range 1 to 22 years). In the dif-
ferent studies, death or permanent end-stage renal dis-
ease (ESRD) ranged from 0 to 30%. Rates of GFR <80
mL/min/1.73m2, hypertension, or overt proteinuria were
extremely variable and ranged from 0% to 64%. To our
knowledge, no previous study has used an asymptomatic
healthy patient control group to quantify the incremental
risk of adverse renal outcomes in those who survive HUS.
Walkerton is a small rural town located in one of On-
tario’s prime agricultural areas. In May 2000, public mu-
nicipal water in Walkerton became contaminated with
E. coli O157:H7 and Campylobacter species. At the time
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of the outbreak, heavy rainfall contributed to the sur-
face transport of livestock fecal contaminants into in-
adequately chlorinated drinking water supplied from a
drilled well. This outbreak produced an estimated 2300
cases of acute gastrointestinal illness, over 750 emergency
room visits, 65 hospital admissions, and 28 pediatric cases
of confirmed HUS, 1 of which was fatal [3]. The Walkerton
Health Study provides a unique opportunity to charac-
terize the association between HUS and long-term renal
sequelae, and guides the need for long-term screening of
individuals exposed to E. coli O157:H7. There are also
issues of financial compensation for those affected by the
environmental disaster [4]. Research questions of this re-
port were: (1) compared to healthy controls, are pediatric
HUS survivors at higher risk of renal sequelae (protein-
uria, hypertension, reduced GFR) 3 years after the initial
infection?; (2) what is the history of identified sequelae at
3 years—are findings progressing, regressing, or remain-
ing constant from the time of initial recovery from HUS?
METHODS
Participants and study design
In May 2000, municipal water in Walkerton became
contaminated with E. coli O157:H7. Phage type 14 was
isolated [5], and the majority of specimens tested for
verotoxin genotype were found to be verotoxin 2. Be-
ginning in February 2002, all surviving individuals who
either lived in the Walkerton area or who had con-
sumed municipal water, irrespective of whether they de-
veloped an acute illness, were invited to participate in the
Walkerton Health Study. The London Health Sciences
Center ethics review board approved the study. Partici-
pants underwent an annual standardized interview, phys-
ical assessment, and laboratory testing by trained staff
unaware of the acute exposure status of the participant.
A review of family physician and hospital charts before,
during, and after the outbreak was conducted with par-
ticipant consent.
Case definition for HUS
In the absence of another medical explanation, chil-
dren with all of the following 3 criteria were defined as
having HUS: (1) a hemoglobin ≤100 g/L with evidence of
destruction of erythrocytes on blood smear; (2) platelets
≤150 × 109/L; and (3) a serum creatinine ≥95th per-
centile for age and sex (for example: age <7 creatinine
≥62 lmol/L; age 7 to 11 ≥76 lmol/L, girls age 12 to 16 ≥89
lmol/L, boys age 12 to 16 ≥109 lmol/L) [6]. In addition,
during the outbreak, strained health care resources led
to limited laboratory testing in some patients. Five chil-
dren with elevated serum creatinine approached but did
not exceed the 95th percentile for age and sex. These
children otherwise met all diagnostic criteria (marked
hemolytic anemia, thrombocytopenia, and red blood cell
casts on urine microscopy), and were characterized as
having HUS by 2 independent physicians.
Selection of controls
Each participant with HUS was matched to 2 children
who were healthy at the time of the outbreak. These con-
trol participants were randomly selected from a group
of 352 healthy eligible children who participated in the
Walkerton Health Study. Cases were frequency matched
to controls in 8 unique stratum, defined by age and sex.
Renal function
Urine albumin to creatinine ratios were calculated on a
random specimen using clean catch techniques and ster-
ile containers [7]. Urine albumin was initially assessed at
the London Health Sciences Center Laboratory with the
IMMULITE 2000 Analyzer (Diagnostic Products Corpo-
ration, Los Angeles, CA, USA), using a solid-phase com-
petitive chemiluminescent enzyme immunoassay. During
the study, testing was moved to the Walkerton laboratory,
which used an IMAGE Beckman Coulter immunoassay
(Beckman Coulter, Fullerton, CA, USA). There was ex-
cellent reliability on 100 duplicate samples sent to both
labs for urine albumin to creatinine ratio measurements
(Pearson correlation R2 = 0.98). Serum and urine crea-
tinine were measured by the modified kinetic method of
Jaffe using a Vitros 950 Auto Analyzer (Johnson & John-
son, Skillman, NJ, USA), with an interassay coefficient of
variation less than 4%. For children, the laboratory serum
creatinine reference range of upper normal for this an-
alyzer was 70 lmol/L for ages 1 to 7, and 90 lmol/L for
ages 8 to 12. The reference normal range was 59 to 117
lmol/L for adult males, and 51 to 95 lmol/L for adult
females. Walkerton serum creatinine was reading on av-
erage 3 lmol/L higher compared to the Cleveland Clinic
(the primary lab for the Modification of Diet in Renal
Disease Study) based on 139 duplicate samples sent to
each lab in 2002.
Urine albumin to creatinine ratios are challenging to
interpret in children because normal levels are not well
established [8]. To facilitate comparisons, in addition to
using a healthy control group within the study, we de-
fined microalbuminuria with similar cut-off points used
in the Third National Health and Nutrition Examination
Survey (NHANES III) [9, 10]. In NHANES III, 5000
healthy participants ages 6 to 19 years were assessed for
microalbuminuria, defined by a random urine albumin to
creatinine ratio between 3.4 and 33.9 mg/mmol (30 to 300
mg/g).
GFR was estimated by the Schwartz formula [11]. In
addition, a 24-hour urine was collected for protein. Blood
pressure was assessed in-center by protocol using an ap-
propriate cuff size for measured arm circumference. Staff
unaware of the acute exposure status of the participant
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were trained to perform 3 blood pressure measurements
(2 automated by Dynamap and 1 manual). To reduce vari-
ability, the first blood pressure measurement was ignored,
and second automated and third manual measurements
were averaged.
Analysis
We specified a priori 3 primary continuous renal mea-
sures to be compared between the groups—1 representa-
tive of proteinuria (random urine albumin to creatinine
ratio), clearance (Schwartz calculated GFR), and blood
pressure (mean arterial blood pressure). To account for
multiple comparisons in these primary outcomes, we used
a Bonferroni correction with a two-tailed P value <
0.017, considered significant when interpreting positive
results. Supplementary analyses supporting the primary
outcomes considered a two-tailed P < 0.05 as significant.
To account for the initial matching and small cell sizes,
the group differences on outcomes were assessed using a
mixed model with exposure as the fixed effect and sub-
jects defined by stratum. Supplementary techniques to
confirm the robustness of the primary analyses included
stratified ordinary least squares regression (OLS) and
nonparametric comparisons. Relative risks for microal-
buminuria were calculated as described elsewhere [12], as
stratified logistic regression demonstrated no effect mod-
ification by stratum. Box plots and trends over time were
graphed in Microsoft Excel.
RESULTS
Study enrollment
During the outbreak, there were 28 children with HUS.
One child had proteinuria which predated the outbreak,
and 1 died at the time of the outbreak. Of the remaining
26 children, 1 declined study participation, 1 was unable
to be located, 3 declined complete follow-up measure-
ments, and 2 were from out of the area and were unable to
be contacted. These 7 potentially eligible nonparticipants
were similar to participants in their baseline characteris-
tics and disease severity—their average age at the time
of the outbreak was 4, 4 were male, 2 developed olig-
uria or anuria, and 1 required hemodialysis for 5 days.
The remaining 19 participating children with HUS were
matched to 38 children with no symptoms at the time of
the outbreak.
Baseline characteristics
All participants were Caucasian, and ranged in age
from 1 to 15 years at the time of the outbreak. As shown
in Table 1, there were no significant differences between
the groups in baseline characteristics at the time of the
outbreak. Similarly, as shown in Table 2, there were no
Table 1. Baseline characteristics of children at the time of a
municipal water contamination with E. coli O157:H7 in May 2000
Controls Children with HUS
Number 38 19
Age years 4.8 ± 3.4 4.7 ± 3.8
Female 53% 53%
Birth weight kg 3.4 ± 0.7 3.4 ± 0.8
Family history of:
Kidney failure 2.6% 0%
Diabetes mellitus 2.6% 0%
Hypertension 13.2% 5.3%
Complete data were collected on all participants, with the exception of birth
weight, which was recorded in 44% of medical records. Children who were
asymptomatic at the time of the outbreak (controls) were compared to those
children who developed hemolytic uremic syndrome (HUS). Mean ± standard
deviation.
Table 2. Follow-up characteristics 3 years after a municipal water
contamination with E. coli O157:H7
Controls Children with HUS
Weight kg 29.1 ± 14.4 31.0 ± 16.2
Height cm 128 ± 18 127 ± 20
Body mass index kg/m2 16.9 ± 2.8 17.9 ± 3.4
Body surface area m2 1.0 ± 0.3 1.0 ± 0.3
Time from outbreak to clinic 3.0 ± 0.1 3.0 ± 0.1
visit years
24 hour urine volume mL 549 (239) 567 (274)
Children who were asymptomatic at the time of the outbreak (controls) were
compared to those children who recovered from hemolytic uremic syndrome.
Mean ± standard deviation.
significant differences between the groups in relevant fac-
tors related to renal function testing during follow-up.
Of the 19 children with HUS, all were known to be
previously healthy without medical conditions (such as
diabetes, hypertension, renal disease, recurrent infec-
tions, or failure to thrive) predating the outbreak. At
the time of acute illness, 16 (84%) had stools positive
for E. coli O157:H7 bacteria or verotoxin. The average
lowest hemoglobin was 61 g/L (SD 14, range 45 to 95),
the average lowest platelet count was 56 × 109/L (SD 38,
range 12 to 150), and the average highest serum creati-
nine was 246 lmol/L (SD 248, range 42 to 861). None
developed convulsions, coma, stroke, or severe colitis re-
quiring surgery. Seven anuric children were treated with
peritoneal dialysis for an average of 14 days (range 10 to
19). One child was treated with antihypertensive therapy
acutely. Three children were treated with antihyperten-
sive therapy [an angiotensin converting enzyme inhibitor
(ACE-I)] for variable amounts of time in the 3 years after
HUS (Fig. 3). All the 19 children made an excellent re-
covery in the months following the acute infection—none
required long-term dialysis, and all had a serum creatinine
that returned to the lab defined normal range.
Renal function 3 years after HUS
Renal function tests 3 years after the outbreak are pre-
sented in Table 3. Compared to controls, children who
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Table 3. Renal function testing 3 years after a municipal water contamination with E. coli O157:H7
Controls Children with HUS Significance
Proteinuria
Random urine albumin to creatinine ratio mg/mmol 1.1 ± 1.0 3.0 ± 2.9 P < 0.001
Random urine albumin mg/L 11.0 ± 12.5 32.1 ± 44.9 P = 0.003
24 hr proteinuria mg/day 31 ± 4 31 ± 3 P = 0.94
24 hr proteinuria mg/m2/hour 1.3 ± 1.7 1.2 ± 1.1 P = 0.88
Clearance
Glomerular filtration rate mL/min per 1.73m2a 137 ± 19 127 ± 18 P = 0.06
Serum creatinine lmol/L 46 ± 10 49 ± 10 P = 0.16
Blood pressure
Mean arterial pressure mm Hg 75 ± 7 74 ± 7 P = 0.70
Systolic blood pressure mm Hg 100 ± 8 100 ± 8 P = 0.98
Diastolic blood pressure mm Hg 63 ± 7 62 ± 8 P = 0.60
Children who were asymptomatic at the time of the outbreak (controls) were compared to those children who recovered from hemolytic uremic syndrome (HUS).
Mean ± standard deviation. To convert albumin to creatinine ratio from mg/mmol to mg/g, multiply by 8.84.
aGFR as estimated by Schwartz formula.
0.0
2.0
4.0
6.0
8.0
10.0
N
or
m
a
l
M
ic
ro
al
bu
m
in
u
ria
R
an
do
m
 u
rin
e 
al
bu
m
in
 to
 c
re
at
in
in
e 
ra
tio
,
 
m
g/
m
m
ol
Control
N = 38
HUS
N = 19
Fig. 1. Random urine albumin to creatinine ratios 3 years after a mu-
nicipal water contamination with E. coli O157:H7. Thirty-two percent
of children who recovered from hemolytic uremic syndrome (HUS)
demonstrated microalbuminuria (6 of 19) compared to 5% of controls
who were asymptomatic at the time of the outbreak (2 of 38, P = 0.01).
The boxes represent the interquartile range (50% of the values). The
line across the box indicates the median. The whiskers extend to the
95th and 5th percentile.
recovered from HUS demonstrated more microalbumin-
uria [Fig. 1, random urine albumin to creatinine ratio of
1.1 vs. 3.0 mg/mmol (9.7 vs. 26.5 mg/g), P < 0.001]. Of
subjects with HUS, 32% (6 of 19) had microalbuminuria
compared to 5% (2 of 38) of controls (P = 0.01). The rela-
tive risk of microalbuminuria after HUS was 4.8 (95% CI
1.1 to 22.0). No child in either group had overt protein-
uria, as defined by a random urine albumin to creatinine
ratio >33.9 mg/mmol (300 mg/g).
As shown in Table 3, at 3 years there were no signifi-
cant differences in blood pressure or GFR between HUS
survivors and healthy controls. Five percent of both HUS
children (1/19) and controls (2/38) had a systolic or di-
astolic blood pressure >95th percentile for age and sex.
The difference in Schwartz-estimated GFR between the
groups approached but did not achieve statistical signifi-
cance (Fig. 2; P = 0.06).
In addition to testing at 3 years, most of children who
developed HUS had urine albumin to creatinine testing
1 and 2 years after the acute illness (descriptively pre-
sented in Fig. 3). In the 6 children with microalbuminuria
3 years after HUS, the urine albumin to creatinine ratio
was decreasing with time in 3 children, increasing with
time in 2 children, and stable in 1 child (Fig. 3). Descrip-
tively, those with stable or increasing urine albumin to
creatinine ratios did not appreciably differ in their illness
and treatment characteristics from those with decreasing
levels, other than in the use of ACE-Is.
In those with HUS, none of the following factors dur-
ing the acute illness were statistically associated with in-
creased urine albumin to creatinine ratio or lower GFR 3
years after the outbreak: higher white blood count (≥11.0
vs. <11.0 × 109/L), lower hemoglobin (≤107.5 g/L vs.
>107.5 g/L), lower platelets (≤74.5 vs. >74.5 × 109/L),
higher serum creatinine (≥141 vs. <141 lmol/L), elevated
lactose dehydrogenase (≥1910 vs. <1910 IU/L), or the
presence of fever, anuria, or the need for acute dialysis.
DISCUSSION
Despite its importance, the long-term renal progno-
sis of D+ HUS remains controversial. Here, 3 years af-
ter HUS recovery, one third of children demonstrated
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Fig. 2. Glomerular filtration rate (GFR) 3 years after a municipal water
contamination with E. coli O157:H7. Children who recovered from
hemolytic uremic syndrome (HUS) were not significantly different from
children (controls) who were asymptomatic at the time of the outbreak.
A single child who recovered from HUS demonstrated a GFR less than
89 mL/min per 1.73m2 (value of 77 mL/min per 1.73m2). The boxes
represent the interquartile range (50% of the values). The line across
the box indicates the median. The whiskers extend to the 95th and 5th
percentile.
microalbuminuria. HUS survivors were comparable in
GFR and blood pressure to healthy children, and none
had overt proteinuria.
The outcome of these children at 3 years is better than
expected. Our systematic review summarizing all long-
term studies suggested that an average of 4 years follow-
ing D+ HUS (follow-up range 1 to 22 years), a quarter
of children demonstrate renal abnormalities (GFR less
than 80 mL/min per 1.73m2, hypertension, or overt pro-
teinuria) [2]. Similarly, when follow-up studies of shorter
duration are considered, appreciable renal sequelae in
survivors have been described in most [13–15], but not
all [16] studies. Reasons for differences between our re-
sults and other studies are likely multifactorial, and may
relate to differences in the severity of acute disease or
the use of ACE-I therapy in some children during follow-
up. Furthermore, due to limited statistical power in our
study, we cannot exclude a 10 mL/min per 1.73m2 reduc-
tion in GFR in HUS compared to control participants,
if in truth such a difference did exist. Despite these en-
couraging short-term results, the clinical relevance and
prognostic importance of isolated microalbuminuria in
our children remains uncertain. Similar to other renal
insults, it is has been suggested that D+ HUS can lead
to a critical reduction in nephron number, with unsus-
tainable remnant single-nephron hyperfiltration and pro-
gressive renal disease [17]. Microalbuminuria may be the
first marker of such hyperfiltration, and its importance
in the natural progression of other renal diseases, such
as diabetic nephropathy, is well described. In 2 children
who recovered from HUS, the microalbuminuria level
appeared to increase with time. Thus, longer follow-up
is needed to clarify the clinical significance and utility of
this early finding. In addition, whether those who con-
tracted E. coli O157:H7 gastroenteritis in the absence of
HUS could also demonstrate hypertension, proteinuria,
or chronic kidney disease is an untested research question
for future consideration.
The Walkerton outbreak has had important legal and
financial remuneration implications for those affected.
Communicating the nuances and uncertain prognostic
significance of microalbuminuria to the population, le-
gal experts, and government representatives has proven
challenging.
Our study used the strongest feasible epidemiologic
design, a cohort analytic study, to answer the research
question posed. Unlike other studies where the primary
etiology of HUS was not always certain [18–24], all partic-
ipants in this study were clearly delineated to have HUS
due to E. coli O157:H7. The use of a healthy internal con-
trol group to compare renal outcomes such as microal-
buminuria is particularly important, given the uncertain
prevalence of such findings in the pediatric population. Fi-
nally, the majority of children who developed HUS from
the outbreak were participants in this study.
Despite these merits, limitations of the present re-
search should be appreciated. Random urine specimens
were used here for reasons of feasibility. However, using
first morning urine samples may have reduced measure-
ment variability due to postural changes. While the ho-
mogenous exposure of this study is a strength, these long-
term results may not be generalizable to other strains
of toxogenic E. coli or contact sources other than wa-
ter. Finally, the control group used in this study may
have ingested contaminated municipal water during the
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Fig. 3. Spot urine albumin to creatinine ra-
tios in each of the 19 children who survived
HUS, separated into decreasing, similar, and
increasing trends over time. Microalbumin-
uria was defined by a urine albumin to creati-
nine ratio between 3.4 and 33.9 mg/mmol. In
the 6 children with microalbuminuria 3 years
after HUS, the urine albumin to creatinine ra-
tio was decreasing with time in 3 children, in-
creasing with time in 2 children, and stable
in 1 child. Children who were treated with an
ACE-I during follow-up are highlighted with
a star (∗).
outbreak, but otherwise remained healthy without diar-
rhea. It is conceivable that asymptomatic E. coli O157:H7
exposure results in acute silent renal disease and long-
term microalbuminuria. However, this would bias toward
demonstrating no difference between the groups, a find-
ing that was not present in this study at least for microal-
buminuria. Furthermore, we believe the control group
used in this study represents an appropriate norm, given
their levels of microalbuminuria were equal or less than
healthy children used in population reference standards
[25].
In this study, we conclude D+ HUS caused mi-
croalbuminuria 3 years after recovery. However, the
majority of children had no renal testing before an un-
predictable event like an outbreak. Thus, it could be pro-
posed that a group of children with microalbuminuria
predating the outbreak may have been more suscepti-
ble to E. coli O157:H7 infection and HUS than controls,
which accounts for the microalbuminuria observed at
3 years. While theoretically possible, we believe this to
be implausible for a number of reasons. The HUS sub-
jects were children, and children are unlikely to have
substantial undetected health conditions associated with
microalbuminuria. In addition, the baseline characteris-
tics of HUS participants predating the outbreak were sim-
ilar to healthy controls.
CONCLUSION
Children may demonstrate microalbuminuria 3 years
after recovering from HUS. Longer follow-up of these
participants will clarify the natural history and impor-
tance of this early finding.
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